{
    "clinical_study": {
        "@rank": "14952", 
        "arm_group": [
            {
                "arm_group_label": "NSRH", 
                "arm_group_type": "Experimental", 
                "description": "patients in Arm NSRH undergo nerve-spring radical hysterectomy (NSRH)"
            }, 
            {
                "arm_group_label": "RH", 
                "arm_group_type": "Active Comparator", 
                "description": "patients in Arm RH undergo radical hysterectomy (RH)"
            }
        ], 
        "brief_summary": {
            "textblock": "The investigators designed this multicentre randomized study to investigate the clinical\n      benefits of nerve-spring radical hysterectomy for cervical cancer. Patients with FIGO stage\n      Ia2, Ib1, IIa1 and FIGO stage Ib2, IIa2 after neoadjuvant chemotherapy are randomized to\n      either nerve-spring radical hysterectomy or radical hysterectomy. The primary endpoint are\n      urodynamic  outcome including maximum flow rate, residual volume, maximum vesical compliace,\n      cystomctric capacity at first desire, and maximum cystomctric capacity. A total 240 patients\n      (120 per treatment arm) are planned to accrue for this study within 7 years."
        }, 
        "brief_title": "A Multicentre Trial of Nerve-Spring Radical Hysterectomy vs. Radical Hysterectomy for Cervical Cancer", 
        "completion_date": {
            "#text": "December 2020", 
            "@type": "Anticipated"
        }, 
        "condition": "Cervical Cancer", 
        "condition_browse": {
            "mesh_term": "Uterine Cervical Neoplasms"
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          1. FIGO(2009) stage Ia2, Ib1, and IIa1 Untreated cervical cancer  OR FIGO(2009) stage\n             Ib2 and IIa2 cervical cancer  that possible to surgery after neoadjuvant chemotherapy\n\n          2. Possible to radical hysterectomy or nerve-spring radical hysterectomy\n\n          3. Age: 17 to 60 years\n\n          4. No complication during operation\n\n          5. Written informed consent\n\n        Exclusion Criteria:\n\n          1. patients who  underwent  radiotherapy\n\n          2. Pathologically diagnosed Pathologically diagnosed squamous carcinoma, Small Cell\n             Carcinoma, Small Cell Carcinoma\n\n          3. Patients who have uncontrolled diabetes or uncontrolled hypertension\n\n          4. patients with neurogenic bladder dysfunction\n\n          5. patients with uterine prolapse\n\n          6. Patients with psychiatric illness\n\n          7. Patients who have active infection\n\n          8. Patients who have had heart failure, unstable angina, or myocardial infarction within\n             the past 6 months\n\n          9. Patients who are unable to undergo radical hysterectomy for complication of excessive\n             obesity, liver cirrhosis, or bleeding tendency"
            }, 
            "gender": "Female", 
            "healthy_volunteers": "No", 
            "maximum_age": "60 Years", 
            "minimum_age": "17 Years"
        }, 
        "enrollment": {
            "#text": "240", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "September 25, 2012", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01886508", 
            "org_study_id": "NCT00270426"
        }, 
        "intervention": [
            {
                "arm_group_label": "NSRH", 
                "description": "Nerve-spring radical hysterectomy that is reserve some pelvic  autonomic nerves during radical hysterectomy.  Reserve hypogastric nerve trunk during dissecting cardinal ligament.  Reserve pelvic splanchnic nerve trunk during exsecting uterosacral ligament. Reserve bladder nerve of pelvic plexus during dissecting vesicouterine ligament.", 
                "intervention_name": "Nerve-spring radical hysterectomy", 
                "intervention_type": "Procedure"
            }, 
            {
                "arm_group_label": "RH", 
                "description": "Radical hysterectomy is Piver III  hysterectomy and Q-M classification Type C1 hysterectomy.", 
                "intervention_name": "radical hysterectomy", 
                "intervention_type": "Procedure"
            }
        ], 
        "is_fda_regulated": "No", 
        "lastchanged_date": "July 19, 2013", 
        "location": {
            "contact": {
                "email": "chenchunlinrct@163.com", 
                "last_name": "Chunlin Chen, M.D.,Ph.D."
            }, 
            "facility": {
                "address": {
                    "city": "Guangzhou", 
                    "country": "China", 
                    "state": "Guangdong", 
                    "zip": "510515"
                }, 
                "name": "Southern Medical University, China"
            }, 
            "investigator": {
                "last_name": "Chenlin Chen, M.D.,Ph.D.", 
                "role": "Principal Investigator"
            }, 
            "status": "Not yet recruiting"
        }, 
        "location_countries": {
            "country": "China"
        }, 
        "number_of_arms": "2", 
        "overall_contact": {
            "email": "chenchunlinrct@163.com", 
            "last_name": "Chenlin Chen, M.D.,Ph.D.", 
            "phone": "+8602062787947"
        }, 
        "overall_status": "Not yet recruiting", 
        "oversight_info": {
            "authority": "China: Ministry of Health", 
            "has_dmc": "Yes"
        }, 
        "phase": "N/A", 
        "primary_completion_date": {
            "#text": "December 2017", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": [
            {
                "measure": "maximum flow rate measured by Urodynamic at 6 months postoperative", 
                "safety_issue": "No", 
                "time_frame": "on  6  months  postoperative"
            }, 
            {
                "measure": "residual volume measured by Urodynamic at 6 months postoperative", 
                "safety_issue": "No", 
                "time_frame": "on  6 months  postoperative"
            }, 
            {
                "measure": "maximum vesical compliace measured by Urodynamic at 6 months postoperative", 
                "safety_issue": "No", 
                "time_frame": "on  6 months  postoperative"
            }, 
            {
                "measure": "cystometric capacity at first desire measured by Urodynamic at 6 months postoperative", 
                "safety_issue": "No", 
                "time_frame": "on 6 months  postoperative"
            }, 
            {
                "measure": "maximum cystometric capacity (MCC) measured by Urodynamic at 6 months postoperative", 
                "safety_issue": "No", 
                "time_frame": "on  6 months  postoperative"
            }
        ], 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01886508"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": [
            {
                "measure": "Time (days) to residual urine volume less than 100ml postoperative", 
                "safety_issue": "No", 
                "time_frame": "from operation to residual urine volume less than 100ml, assessed up to 30 days"
            }, 
            {
                "measure": "time (hours) to break wind postoperative", 
                "safety_issue": "No", 
                "time_frame": "from operation to have the first break wind, assessed up to 72 hours"
            }, 
            {
                "measure": "time (hours) to defecation postoperative", 
                "safety_issue": "No", 
                "time_frame": "from operation to have the first defection, assessed up to 72 hours"
            }, 
            {
                "measure": "Number  of  participants  with  adverse events", 
                "safety_issue": "Yes", 
                "time_frame": "From date of operation until the date of first documented adverse event or date of death from any cause, whichever came first, assessed up to 5 years"
            }, 
            {
                "measure": "Score of MHU rating scales at 6 months postoperative", 
                "safety_issue": "No", 
                "time_frame": "on  6 months  postoperative"
            }, 
            {
                "measure": "overall survival", 
                "safety_issue": "Yes", 
                "time_frame": "From date of operation until the date of death from any cause, assessed up to 5 years"
            }, 
            {
                "measure": "progression-free survival", 
                "safety_issue": "Yes", 
                "time_frame": "From date of operation until the date of relapse or date of death from any cause, whichever came first, assessed up to 5 years"
            }, 
            {
                "measure": "Score of C-30 life quality rating scales at 6 months postoperative", 
                "safety_issue": "No", 
                "time_frame": "on  6 months  postoperative"
            }, 
            {
                "measure": "Score of CX-24 life quality rating scales at 6 months postoperative", 
                "safety_issue": "No", 
                "time_frame": "on  6 months  postoperative"
            }
        ], 
        "source": "Nanfang Hospital of Southern Medical University", 
        "sponsors": {
            "collaborator": [
                {
                    "agency": "Tumor Hospital of Xin Jiang Medical University,China", 
                    "agency_class": "Other"
                }, 
                {
                    "agency": "Gui Yang Maternal and Child Health Hospital,China", 
                    "agency_class": "Other"
                }, 
                {
                    "agency": "China People's Liberation Army No. 152 Centre Hospital", 
                    "agency_class": "Other"
                }
            ], 
            "lead_sponsor": {
                "agency": "Nanfang Hospital of Southern Medical University", 
                "agency_class": "Other"
            }
        }, 
        "start_date": "July 2013", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "May 2013"
    }
}